Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing

作者：Bianhong Wang, Yangyang Liu, Guangyuan Hou, Lili Wang, Na Lv, Yuanyuan Xu, Yihan Xu, Xiuli Wang, Zhaoling Xuan, Yu Jing, Honghua Li, Xiangshu Jin, Ailing Deng, Li Wang, Xiaoning Gao, Liping Dou, Junbin Liang, Chongjian Chen, Yonghui Li, Li Yu · 发表于：Oncotarget · 年份：2016 · DOI：10.18632/oncotarget.7028 · 被引用次数：41 · 研究领域：Acute Myeloid Leukemia Research、Multiple Myeloma Research and Treatments、Cancer Genomics and Diagnostics

// Bianhong Wang 1, * , Yangyang Liu 3, * , Guangyuan Hou 3 , Lili Wang 2 , Na Lv 2 , Yuanyuan Xu 2 , Yihan Xu 2 , Xiuli Wang 3 , Zhaoling Xuan 3 , Yu Jing 2 , Honghua Li 2 , Xiangshu Jin 2 , Ailing Deng 2 , Li Wang 2 , Xiaoning Gao 2 , Liping Dou 2 , Junbin Liang 3 ,Chongjian Chen 3, * , Yonghui Li 2, * , Li Yu 2, * 1 Medical Center, Tsinghua University, Beijing 100084, China 2 Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China 3 Research and Development Department, Annoroad Gene Technology Co. Ltd, Beijing 100176, China * These authors have contributed equally to this work Correspondence to: Li Yu, email: chunhuiliyu@yahoo.com Yonghui Li, email: yonghuililab@163.com Chongjian Chen, email: cchen@annoroad.com Keywords: intermediate-risk acute myeloid leukemia, next generation sequencing, mutational screening and analysis, risk stratification Received: June 29, 2015     Accepted: January 13, 2016     Published: January 27, 2016 ABSTRACT Intermediate-risk acute myeloid leukemia (IR-AML), which accounts for a substantial number of AML cases, is highly heterogeneous. Although several mutations have been identified, the heterogeneity of AML is uncertain because novel mutations have yet to be discovered. Here we applied next generation sequencing (NGS) platform to screen mutational hotspots in 410 genes relevant to hematological malignancy. IR-AML samples (N=95) were sequenced by Illumina Hiseq and mutations in 101 ...